GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Adaptimmune
Adaptimmune is a pioneering company in T-cell therapy for solid tumors. Its stock price represents a venture bet on its scientific platform. The stock price reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Oncology cell gene therapy
Adaptimmune is a British biotech company pioneering the development of T-cell receptor (TCR)-based cell therapies for the treatment of solid tumors. We've categorized it under "Oncology: Cell Therapies." The chart below shows how investors view this cutting-edge sector in the fight against cancer.
Broad Market Index - GURU.Markets
Adaptimmune is a biotech company pioneering the development of T-cell therapy for solid tumors. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. See how Adaptimmune shares compare to sentiment in the biotech sector.
Change in the price of a company, segment, and market as a whole per day
ADAP - Daily change in the company's share price Adaptimmune
For Adaptimmune Therapeutics, a cell therapy company, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in this innovative field of oncology.
Daily change in the price of a set of shares in a market segment - Oncology cell gene therapy
Adaptimmune Therapeutics plc is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with ADAP, a pioneer in cell therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Adaptimmune is a pioneer in developing T-cell therapy for solid tumors. The company's shares move in sync with scientific discoveries and clinical data. This high, innovation-driven volatility is part of the dynamics of the entire biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Adaptimmune
Adaptimmune Therapeutics's growth is a story of developing T-cell receptor (TCR)-based cell therapies. Its 12-month market cap is entirely dependent on clinical trial data. Successful approval of its first drug for sarcoma will be a fundamental validation of its scientific platform and usher in a new era in the treatment of solid tumors.
Annual dynamics of market capitalization of the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics plc is a leader in developing T-cell therapies for solid tumors. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks associated with this cutting-edge field of medicine.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adaptimmune is a cutting-edge cell therapy company, and its stock is driven by lab news. Its year-over-year performance relative to the market isn't about economics, but rather about the hope for a revolution in cancer treatment. Success in trials can boost the stock by hundreds of percent, demonstrating a complete disconnect from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Adaptimmune
Adaptimmune is a pioneer in T-cell therapy development. Its monthly performance is driven by clinical and regulatory developments. News about the results of its solid tumor drug trials and its interactions with the FDA drive strong share price movements.
Monthly dynamics of market capitalization of the market segment - Oncology cell gene therapy
This chart reflects the dynamics of the cutting-edge cell therapy sector. For Adaptimmune, one of the pioneers, it's the backdrop. Its movements illustrate how investor expectations related to the approval of its drugs and clinical trial data are impacting the entire industry.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Adaptimmune Therapeutics is a leader in developing T-cell therapy (TCR-T) for the treatment of solid tumors. This is a revolutionary but high-risk field. The overall market has little impact on Adaptimmune; its shares are driven by news of clinical trials, and a single success could trigger explosive growth, defying any macroeconomic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Adaptimmune
Adaptimmune, a pioneer in T-cell cancer therapy, is extremely sensitive to scientific news. Its weekly stock price is a sharp reaction to the release of clinical trial data, regulatory approvals (FDA), and news of partnerships with major pharmaceutical companies validating its platform.
Weekly dynamics of market capitalization of the market segment - Oncology cell gene therapy
Adaptimmune operates in the revolutionary cell therapy sector, where shared technological breakthroughs and regulatory decisions impact everyone. The success of one company can boost the entire segment. The graph will show whether ADAP is perceived by the market as a leader in this movement or simply part of it, moving with the flow.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
As a biotech company, Adaptimmune often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how ADAP shares can rise or fall on news releases while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
ADAP - Market capitalization of the company Adaptimmune
Adaptimmune's chart is a visual representation of the promise of T-cell therapy for solid tumors. This biotech's valuation is a roller coaster ride, with every clinical trial result potentially leading to a dramatic rise or fall. It's a bet on one of the most complex, yet promising, approaches in oncology.
ADAP - Share of the company's market capitalization Adaptimmune within the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a pioneer in T-cell therapy for solid tumors. Its market share in the biotech sector is based on its cutting-edge scientific platform. The chart shows how the market views its progress in developing "living drugs" that use a patient's own cells to fight cancer.
Market capitalization of the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in developing T-cell therapies for solid tumors. The chart below shows the market capitalization of the cell-based oncotherapy sector. This represents one of the most complex, yet most promising, areas in the fight against cancer.
Market capitalization of all companies included in a broad market index - GURU.Markets
Adaptimmune is a pioneer in T-cell therapy for solid tumors. Its market cap is a bet on a breakthrough in this complex area of oncology. The chart below shows the economic weight of the cell therapy sector fighting solid tumors.
Book value capitalization of the company, segment and market as a whole
ADAP - Book value capitalization of the company Adaptimmune
Adaptimmune is built on cutting-edge cell therapy. Its book value reflects its patents for T-cell receptor (TCR) engineering technology for treating solid tumors, as well as its own manufacturing capacity and R&D capital. The chart below illustrates how the company built its complex scientific and manufacturing foundation.
ADAP - Share of the company's book capitalization Adaptimmune within the market segment - Oncology cell gene therapy
Adaptimmune develops cell therapies with its own R&D and manufacturing centers. This unique scientific infrastructure is its main material asset. The S_BCap_Seg chart shows its share of the physical assets in the innovative gene therapy sector.
Market segment balance sheet capitalization - Oncology cell gene therapy
Adaptimmune Therapeutics is a pioneer in T-cell therapy for cancer. Its value lies in its cutting-edge scientific platform and clinical development. A book value chart shows that its assets are almost entirely intangible, which is typical for companies at the forefront of oncology.
Book value of all companies included in the broad market index - GURU.Markets
Adaptimmune's assets are living drug manufacturing plants. The company's book value reflects its state-of-the-art manufacturing centers in the US and UK, where patients' T cells are genetically modified to fight cancer. This is a capital-intensive resource for creating one of the most complex forms of personalized medicine.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Adaptimmune
Adaptimmune is a pioneer in T-cell therapy for solid tumors. Its book value represents funding for research. Its market capitalization is a pure valuation of its cutting-edge scientific platform and the potential of its drug candidates to deliver breakthroughs in cancer treatment.
Market to book capitalization ratio in a market segment - Oncology cell gene therapy
Adaptimmune is a leader in developing T-cell therapies for solid tumors. This is at the forefront of biotechnology. The chart shows the significant market premium placed on its scientific platform and potential for cancer treatment compared to the value of its laboratories.
Market to book capitalization ratio for the market as a whole
Adaptimmune is a pioneer in T-cell therapy for cancer. The company's value is almost entirely dependent on the success of its scientific platform. The chart below demonstrates how the market valuation reflects investor confidence in the breakthrough technology, creating a significant gap with the current book value.
Debts of the company, segment and market as a whole
ADAP - Company debts Adaptimmune
Adaptimmune, a leader in cancer cell therapy, uses debt to fund its capital-intensive research and production. This chart shows the company's massive funding for late-stage clinical trials and the construction of its own T-cell therapy manufacturing facilities.
Market segment debts - Oncology cell gene therapy
Adaptimmune is a leading company developing TCR cell therapies for the treatment of solid tumors. These technologies are extremely expensive to develop and manufacture, requiring hundreds of millions of dollars in investment. This chart shows how the company funds its cutting-edge, yet capital-intensive, cancer research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Adaptimmune
Adaptimmune Therapeutics is a leader in developing cell therapies for cancer. This chart shows whether the company uses debt to finance its cutting-edge and very expensive research. In this biotech sector, debt is a huge risk, but it also offers an opportunity to bring life-saving treatments to patients faster, which is reflected in the company's financial strategy.
Market segment debt to market segment book capitalization - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in cancer cell therapy. This chart from the cutting-edge biotech industry shows how much capital it raises to fund breakthrough, but very expensive, research. It provides context for evaluating the company's financial strategy in one of the most promising areas of oncology.
Debt to book value of all companies in the market
Adaptimmune is a biotech company at the forefront of cell therapy, developing T-cell therapy for cancer. This chart, showing the market's debt-to-book value ratio, is important for assessing the investment climate. The market's willingness to finance breakthrough but capital-intensive technologies determines Adaptimmune's ability to move forward.
P/E of the company, segment and market as a whole
P/E - Adaptimmune
Adaptimmune Therapeutics is a leader in developing T-cell therapies for solid tumors. This chart reflects hopes for a breakthrough in cancer treatment. The high value of this indicator reflects the high expectations surrounding its cutting-edge scientific platform, which could lead to a new class of powerful drugs for patients with difficult-to-treat cancers.
P/E of the market segment - Oncology cell gene therapy
Adaptimmune, like other biotechs, is in a sector with high expectations. This chart shows the average P/E ratio for this industry. A company's P/E is higher than average, indicating that investors consider its T-cell therapy technology particularly disruptive and are willing to pay a premium for it compared to other oncology developments.
P/E of the market as a whole
Adaptimmune Therapeutics is a leader in developing T-cell therapies for solid tumors. This is one of the most advanced and complex approaches in oncology. This chart illustrates the risk appetite in biotech. The company's valuation depends entirely on the success of its clinical trials and investor confidence that it will overcome the enormous scientific challenges and develop an effective treatment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Adaptimmune
Adaptimmune Therapeutics is a leader in developing T-cell receptor (TCR)-based cell therapies for the treatment of solid tumors. The chart reflects investor expectations for future revenue, which depend on the approval and commercial success of its first drugs. This is a bet on a breakthrough in cancer treatment.
%20P%2FE%20Adaptimmune&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Adaptimmune&v=1772373090743 "Chart of the company's future (projected) P/E Adaptimmune")
Future (projected) P/E of the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a pioneer in T-cell therapy, developing drugs for the treatment of solid tumors. This chart shows its future profitability expectations, allowing us to assess how highly the market values its scientific platform and potential for developing breakthrough cancer treatments.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-cell-gene-therapy&v=1772373090744 "Future (projected) P/E graph of the market segment - Oncology cell gene therapy")
Future (projected) P/E of the market as a whole
Adaptimmune is a biotech company pioneering the development of T-cell therapy for solid tumors. This is a cutting-edge and risky area of oncology. The company's valuation is entirely dependent on clinical trial results and is not tied to the overall market forecasts shown in the chart.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772373090745 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Adaptimmune
Adaptimmune Therapeutics is a clinical-stage biotechnology company focused on developing innovative T-cell therapies for cancer. Its financial performance reflects significant investment in research and development. This chart illustrates the capital expenditures required to bring cutting-edge cancer treatments to market.
Profit of companies in the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of T-cell therapies for solid tumors. This chart shows the profitability of the oncology sector. The company's R&D expenditures are enormous, but its breakthrough technology could usher in a new era of cancer treatment and become a powerful driver of future growth for the entire industry.
Overall market profit
Adaptimmune Therapeutics is a leader in developing T-cell therapies for solid tumors. The company's value and future depend entirely on the success of its clinical programs and its ability to bring innovative treatments to market. This chart illustrates general economic cycles, which do not impact Adaptimmune's scientific progress or potential in the fight against cancer.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Adaptimmune
Adaptimmune Therapeutics is a pioneer in cell therapy, developing T-cell therapy for solid tumors. This chart reflects analysts' future earnings expectations based on the potential of this cutting-edge technology. It demonstrates market confidence in the company's ability to successfully commercialize this new class of anticancer drugs.
%20profit%20of%20the%20company%20Adaptimmune&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Adaptimmune&v=1772373090752 "Graph of future (projected) profit of the company Adaptimmune")
Future (predicted) profit of companies in the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics plc is a leader in developing T-cell therapies for cancer. This chart shows profitability projections for the cell and gene therapy oncotherapy sector. It reflects high expectations for breakthrough treatments that could offer new options for patients with solid tumors.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-cell-gene-therapy&v=1772373090752 "Graph of future (predicted) profits of companies in a market segment - Oncology cell gene therapy")
Future (predicted) profit of the market as a whole
Adaptimmune is developing cell therapy for cancer treatment. Like most biotech companies, their overall market revenue forecast is important for their investment climate. Expected economic growth facilitates raising the hundreds of millions of dollars needed to conduct final-stage clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772373090753 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Adaptimmune
Adaptimmune is a biotech company developing T-cell therapy for cancer. Following the recent approval of its first product, P/S is becoming a key metric. It will reflect investors' perception of the company's commercial launch and the potential of its innovative oncology platform.
P/S market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in developing T-cell therapy for solid tumors. Their technology "reprograms" a patient's own immune cells to fight cancer. This chart reflects the market's high expectations for their cutting-edge scientific platform and potential to become a new standard in oncology, which is reflected in their high valuation.
P/S of the market as a whole
Adaptimmune is a leader in developing T-cell therapies for solid tumors. The company's revenue currently comes from affiliate fees, not from product sales. This chart, based on actual revenue, clearly demonstrates that Adaptimmune's valuation is a bet on the future commercial success of its cutting-edge scientific platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Adaptimmune
Adaptimmune is a leader in developing T-cell therapies for solid tumors. This is one of the most advanced and sophisticated approaches in oncology. This chart reflects investor expectations for future revenue from this potentially revolutionary technology, which could be enormous if the company is successful in treating common cancers.
%20P%2FS%20Adaptimmune&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Adaptimmune&v=1772373090757 "The graph of the company's future (projected) P/S Adaptimmune")
Future (projected) P/S of the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics plc is a leader in T-cell therapy for solid tumors. This chart shows how the market perceives the future commercial potential of its cutting-edge oncology platform. It compares it to other companies in the cell gene therapy sector, reflecting the high expectations for its clinical development.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-cell-gene-therapy&v=1772373090759 "Future (projected) P/S market segment graph - Oncology cell gene therapy")
Future (projected) P/S of the market as a whole
Adaptimmune is a leader in developing T-cell therapies for solid tumors, one of the most advanced and sophisticated approaches in modern oncology. This chart shows overall market revenue expectations, and ADAP is a prime example of how investor confidence in breakthrough scientific platforms is driving high expectations for future growth.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772373090765 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Adaptimmune
Adaptimmune Therapeutics is a clinical-stage biotechnology company leading the development of T-cell therapies for the treatment of solid tumors. Currently, its revenue is generated not from commercial product sales, but rather from upfront and milestone payments through strategic partnerships with major pharmaceutical companies.
Sales of companies in the market segment - Oncology cell gene therapy
Adaptimmune is a leader in developing T-cell therapies for cancer. This chart shows revenue from its first commercial product. It allows investors to track the dynamics of initial sales, which is key to assessing the commercial potential of its innovative therapeutic platform.
Overall market sales
Adaptimmune Therapeutics is a leader in developing T-cell therapies for cancer. Its value and prospects depend entirely on success in clinical trials and the commercialization of its breakthrough treatments. This overall market performance graph bears no relation to the factors determining Adaptimmune's future.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Adaptimmune
Adaptimmune Therapeutics is a biopharmaceutical company developing T-cell therapy for cancer. Its revenue forecast depends on the success of clinical trials and the future commercial potential of its cell-based products. This chart shows analyst expectations for its innovative oncology platform.
%20sales%20of%20the%20company%20Adaptimmune&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Adaptimmune&v=1772373090770 "Schedule of future (projected) sales of the company Adaptimmune")
Future (projected) sales of companies in the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in developing T-cell therapies for the treatment of oncology. This chart displays projected revenue for the entire cell and gene therapy segment of oncotherapy. It provides insight into how rapidly analysts expect this cutting-edge market to grow, which is critical to Adaptimmune's future commercial success.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-cell-gene-therapy&v=1772373090771 "Schedule of future (projected) sales of companies in the market segment - Oncology cell gene therapy")
Future (projected) sales of the market as a whole
Adaptimmune is a company developing cell therapy (T-cells) for cancer treatment. Its future depends entirely on the success of clinical trials and regulatory approval. This graph of overall market expectations reflects the investment climate, which is critical to raising the hundreds of millions of dollars needed to bring this innovative therapy to market.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772373090772 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Adaptimmune
Adaptimmune Therapeutics is a clinical-stage company pioneering the development of T-cell therapies for cancer. This chart reflects its current status as a research-focused company. It shows the extent of its investment in developing breakthrough treatments, the success of which determines its future.
Market segment marginality - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in cell therapy, developing T-cell receptors (TCRs) for the treatment of solid tumors. This chart shows the average profitability of the gene and cell therapy oncotherapy sector. It serves as a benchmark for assessing the enormous commercial potential of Adaptimmune's platform if its advanced treatments prove effective.
Market marginality as a whole
Adaptimmune Therapeutics is a leader in developing T-cell therapies for cancer, one of the most advanced and complex areas in medicine. This revenue chart shows today's progress, while Adaptimmune is creating the medicine of tomorrow, where the human immune system will be the primary weapon against cancer.
Employees in the company, segment and market as a whole
Number of employees in the company Adaptimmune
Adaptimmune Therapeutics is a leader in the development of T-cell therapies for cancer. The growth of its highly qualified team of scientists and clinicians, visible in the graph, is directly related to progress in clinical trials and the establishment of its own manufacturing facility, which is key to the commercialization of this complex technology.
Share of the company's employees Adaptimmune within the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a leader in developing T-cell therapies for solid tumors. This chart demonstrates its cutting-edge scientific capabilities. It reflects the significant number of leading immunologists, oncologists, and cell engineers working on the development of next-generation "living therapies" for cancer that Adaptimmune brings together.
Number of employees in the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics plc is a leader in developing T-cell therapies for cancer. This chart shows employment in the oncology cell and gene therapy sector. The rapid growth of scientists in this cutting-edge field reflects the revolution in cancer treatment and the massive investment in immune cell programming technologies.
Number of employees in the market as a whole
Adaptimmune Therapeutics plc is a biotechnology company, a leader in the development of T-cell therapy for the treatment of cancer. Cell and gene therapy are revolutionizing medicine. This graph shows overall employment, and these companies are at the cutting edge of science, creating jobs for highly qualified specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Adaptimmune (ADAP)
Adaptimmune is a leader in cell therapy, one of the most complex and research-intensive areas of medicine. This chart shows the colossal market premium for leadership in this field. The astronomical market capitalization per employee reflects the unique knowledge and patents held by this team alone.
%20of%20the%20company%20Adaptimmune%20(ADAP)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Adaptimmune-ADAP&v=1772373090783 "Chart of market capitalization per employee (in thousands of dollars) of the company Adaptimmune (ADAP)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Adaptimmune is a leader in developing T-cell therapies for cancer. In this cutting-edge biotech field, its market capitalization per employee reflects the enormous potential of its scientific platform. Its sky-high valuation, compared to other sectors, reflects investor hopes for a revolutionary cancer treatment.
%20by%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-cell-gene-therapy&v=1772373090786 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology cell gene therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Adaptimmune is a leader in developing T-cell therapies for solid tumors. This is one of the most advanced and complex approaches in oncology. This chart reflects the investors' high hopes that the team of scientists will be able to commercialize this revolutionary technology and change the paradigm of cancer treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772373090788 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Adaptimmune (ADAP)
Adaptimmune is a biotech company developing advanced cell therapy (TCR T cells) for the treatment of solid tumors. This is one of the most complex R&D processes. This graph, in negative territory, shows how much capital is being burned for each scientist working on this personalized therapy.
%20Chart%20Adaptimmune%20(ADAP)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Adaptimmune-ADAP&v=1772373090792 "Company Profit Per Employee (in thousands of dollars) Chart Adaptimmune (ADAP)")
Profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy
Adaptimmune Therapeutics is a biotech company developing innovative T-cell therapy for cancer. In the field of cell therapy, this chart reflects the potential value of their scientific platform. It demonstrates the enormous profit potential of a successful therapy developed by a small but highly skilled team of scientists, a key consideration for investors.
%20in%20the%20market%20segment%20-%20Oncology%20cell%20gene%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-cell-gene-therapy&v=1772373090794 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology cell gene therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Adaptimmune is a biopharmaceutical company leading the development of T-cell receptor (TCR) therapies for the treatment of solid tumors. This is a cutting-edge, yet highly expensive, area of R&D. This chart reflects the company's massive investment in each of its scientists and physicians to advance this complex cell therapy through clinical trials.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772373090795 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Adaptimmune (ADAP)
Adaptimmune is a company developing cell therapy for cancer. This chart doesn't reflect commercial viability at the clinical trial stage. It illustrates investments in breakthrough technologies. If its drugs are successful, revenue per employee will skyrocket.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Adaptimmune-ADAP&v=1772373090797 "Sales chart per company employee Adaptimmune (ADAP)")
Sales per employee in the market segment - Oncology cell gene therapy
Adaptimmune (ADAP) is a leader in cell therapy (TCR T cells) for the treatment of solid tumors. This is a complex, personalized medicine. This chart shows the average revenue per employee in the pharmaceutical segment. For ADAP, which is on the threshold of commercialization, comparison to this benchmark demonstrates their transition from an R&D company to a commercial organization.
Sales per employee for the market as a whole
Adaptimmune (ADAP) is a late-stage biotech company developing cell therapy for oncology. The company is preparing for commercialization, but its revenue metric is currently close to zero. Investors are awaiting FDA approval, which should lead to a sharp increase in revenue and the beginning of monetization of their years of R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Adaptimmune (ADAP)
Adaptimmune is a biotech company working at the forefront of science. They are developing T-cell receptor (TCR) therapy for the treatment of solid tumors. This is an extremely complex and expensive technology. This chart shows the activity of the bears, who are betting that their approach will be ineffective against solid tumors or too toxic.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Adaptimmune-ADAP&v=1772373090801 "Short Shares Chart for the Company Adaptimmune (ADAP)")
Shares shorted by market segment - Oncology cell gene therapy
Adaptimmune (ADAP) is a pioneer in TCR-T cell therapy for solid tumors. This is an extremely complex science. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that cell therapy doesn't work against solid tumors. Investors doubt ADAP will be able to overcome the scientific hurdles and prove the efficacy of its "living" drugs.
Shares shorted by the overall market
Adaptimmune (ADAP) is a biotech company in the field of cell therapy. It's one of the most cutting-edge and speculative technologies. When this market fear indicator rises, investors aren't willing to wait 10 years. They're selling off unprofitable "research projects" en masse, like ADAP, to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Adaptimmune (ADAP)
Adaptimmune is a cutting-edge biotech company developing T-cell therapy for cancer, one of the most complex and promising areas in medicine. This chart measures the speculation fever. It shows how any clinical data release can cause investor interest to overheat to extreme levels.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Adaptimmune-ADAP&v=1772373090805 "RSI 14 indicator chart for the company's stock Adaptimmune (ADAP)")
RSI 14 Market Segment - Oncology cell gene therapy
Adaptimmune is a pioneer in cell therapy. They specialize in engineering T-cell receptors (TCR-T) to recognize and destroy solid tumors. This is cutting-edge R&D in oncology. This chart reflects the general sentiment in the genetic engineering sector. It helps assess how overheated this futuristic biotech segment is.
RSI 14 for the overall market
Adaptimmune (ADAP) is a biotech R&D company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ADAP (Adaptimmune)
Adaptimmune is a biopharmaceutical company at the forefront of cell therapy. It develops genetically engineered T cells (TCRs) to attack hard tumors such as sarcoma. This chart shows the speculative average price target from analysts, which is almost entirely based on their faith in this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ADAP-Adaptimmune&v=1772373090809 "A chart showing analyst consensus forecasts for the expected stock price. ADAP (Adaptimmune)")
The difference between the consensus estimate and the actual stock price ADAP (Adaptimmune)
Adaptimmune is a leader in cell therapy. The company is developing enhanced T cells (SPEAR) to attack solid tumors. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this complex oncology platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ADAP-Adaptimmune&v=1772373090810 "A chart showing the difference between the consensus forecast and the actual stock price. ADAP (Adaptimmune)")
Analyst consensus forecast for stock prices by market segment - Oncology cell gene therapy
Adaptimmune is a biotech pioneer developing T-cell therapy (TCR-T) to attack solid tumors—the "holy grail" of cell therapy. This chart shows general expectations for the cell therapy sector. It reflects whether experts believe a breakthrough in solid tumor treatment is possible.
Analysts' consensus forecast for the overall market share price
Adaptimmune is a biotech company pioneering the development of cell-based therapies (TCR-T) for the treatment of solid tumors, which are much more complex than blood cancers. This chart shows the overall risk appetite in the market. For Adaptimmune, working in one of the most complex areas of oncology, overall market optimism is critical for funding R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Adaptimmune
Adaptimmune is a pioneer in cell therapy. They are developing enhanced T-cell (TCR-T) therapies that are designed to detect and attack not only blood cancers (like CAR-T) but also solid tumors (lung, liver). This graph is a clear indicator of their R&D. It reflects their (very risky) progress in clinical trials and their race to crack solid tumors.
AKIMA Market Segment Index - Oncology cell gene therapy
Adaptimmune (ADAP) is a leader in cell therapy. They develop engineered T-cell receptors (TCR-T) to recognize and destroy solid tumors, one of the most challenging areas in oncology. The chart shows the segment's average index, helping investors assess how this cutting-edge scientific platform stacks up against the average risk profile of the sector.
The AKIM Index for the overall market
Adaptimmune is a leader in TCR T-cell therapy for solid tumors (sarcoma). This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for assessing the prospects of this commercial cell therapy.
